Tag Archives: surgical

Obese people deserve surgical treatment, too | Richard Welbourn

One in four people in the UK suffer with obesity. Severe and complex obesity is a lifelong condition associated with many major medical problems, the costs of which threaten to bankrupt the NHS. The major ailment caused by obesity – type 2 diabetes – is linked to shorter life expectancy, decreased quality of life and increased socio-economic and psychosocial problems. A new report out this week suggests the global cost of treating obesity will rise to $ 1.2tn a year from 2025.

Yet in the UK, less than 1% of those who can benefit from it receive bariatric (sometimes called weight-loss) surgery, such as gastric bypass or gastric banding. So why is a safe, cost-effective therapy for a deadly disease so under-utilised?

For severely obese people, the hormonal effects of being obese mean that medical therapies, lifestyle changes and attempts at dieting rarely succeed in maintaining long-term, clinically beneficial weight loss. It isn’t just surgeons saying this – it is described in guidance by the British Obesity and Metabolic Surgery Society which is endorsed by 21 other professional organisations, including nine medical royal colleges.

The World Health Organisation identifies obesity as a chronic disease. But on the other side we have the popular perception – shared by some healthcare professionals – that it is purely a lifestyle choice. This totally disregards the fact that, driven by powerful food industry advertising, it is those who are poor who are most affected. Our tendency towards obesity is rooted in evolutionary biology: human beings have spent two million years developing a metabolic system which conserves energy in times of scarcity. It is only in the last 70 years that we no longer eat because of hunger alone.

The annual volume of bariatric surgery in the UK – about 5,000 operations a year – is five to 10 times lower compared with other European countries with similar population sizes and disease prevalence. In France, which has a similar population size to the UK, more than 37,000 surgeries are carried out each year. Belgium, with a population of 11.3 million, undertakes 12,000 surgeries while Sweden, with a population of 9.9 million, carries out more than 7,000 a year.

As a practising bariatric surgeon, I and my colleagues believe the social stigma of obesity is holding back the deployment of cost-effective treatments for vulnerable people. Health commissioners are aware of the figures, but remain slow to increase provision. Cost can’t be the issue. Getting a patient off insulin or other expensive anti-diabetes medications is cost-saving within two to three years of surgery: a win-win for the GP, the NHS and the taxpayer. Patients are also more likely to go back to work, and therefore pay more tax and claim fewer benefits.

I believe the problem is that commissioners and medical professionals, like the public, still see obesity as a lifestyle choice, and so blame patients. But there is a point of no return with obesity. There are parallels with other diseases. You may well suggest to someone who is a bit down in various ways for them to try and improve their mood, but once they become clinically depressed expert treatment is needed. We encourage our friends to stop smoking, but we don’t then begrudge them treatment for lung cancer.

Yet the reluctance to treat obesity lingers. Some argue that resources should be directed to prevention rather than treatment. Whenever possible, prevention is obviously better than cure. But this is no longer an option for people who have missed the boat of prevention and have gone on to develop severe, complex obesity with conditions such as diabetes.

Patients should be given quicker access to surgical assessment. If bariatric surgery is right for them, then the sooner the better. We already know that the UK is one of the most obese countries in Europe, and the patients we operate on are the sickest. The NHS should be performing 50,000 surgeries a year, closer to the European average.

To achieve this, health workers must be persuaded to put prejudice to one side and promote surgery where appropriate. GPs and commissioners alike must recognise both the health benefits and cost savings.

All the clinical evidence points to the fact that, as a country, we should be performing more weight-loss surgeries. It is the social stigma of obesity that is holding us back. Making fun of obese people is an endemic societal prejudice, and stigmatisation is allowed – and even encouraged – by the media. It’s time to stop judging and let the experts start treating the condition.

Richard Welbourn is a consultant bariatric surgeon at Musgrove Park Hospital, Taunton

Obese people deserve surgical treatment, too | Richard Welbourn

One in four people in the UK suffer with obesity. Severe and complex obesity is a lifelong condition associated with many major medical problems, the costs of which threaten to bankrupt the NHS. The major ailment caused by obesity – type 2 diabetes – is linked to shorter life expectancy, decreased quality of life and increased socio-economic and psychosocial problems. A new report out this week suggests the global cost of treating obesity will rise to $ 1.2tn a year from 2025.

Yet in the UK, less than 1% of those who can benefit from it receive bariatric (sometimes called weight-loss) surgery, such as gastric bypass or gastric banding. So why is a safe, cost-effective therapy for a deadly disease so under-utilised?

For severely obese people, the hormonal effects of being obese mean that medical therapies, lifestyle changes and attempts at dieting rarely succeed in maintaining long-term, clinically beneficial weight loss. It isn’t just surgeons saying this – it is described in guidance by the British Obesity and Metabolic Surgery Society which is endorsed by 21 other professional organisations, including nine medical royal colleges.

The World Health Organisation identifies obesity as a chronic disease. But on the other side we have the popular perception – shared by some healthcare professionals – that it is purely a lifestyle choice. This totally disregards the fact that, driven by powerful food industry advertising, it is those who are poor who are most affected. Our tendency towards obesity is rooted in evolutionary biology: human beings have spent two million years developing a metabolic system which conserves energy in times of scarcity. It is only in the last 70 years that we no longer eat because of hunger alone.

The annual volume of bariatric surgery in the UK – about 5,000 operations a year – is five to 10 times lower compared with other European countries with similar population sizes and disease prevalence. In France, which has a similar population size to the UK, more than 37,000 surgeries are carried out each year. Belgium, with a population of 11.3 million, undertakes 12,000 surgeries while Sweden, with a population of 9.9 million, carries out more than 7,000 a year.

As a practising bariatric surgeon, I and my colleagues believe the social stigma of obesity is holding back the deployment of cost-effective treatments for vulnerable people. Health commissioners are aware of the figures, but remain slow to increase provision. Cost can’t be the issue. Getting a patient off insulin or other expensive anti-diabetes medications is cost-saving within two to three years of surgery: a win-win for the GP, the NHS and the taxpayer. Patients are also more likely to go back to work, and therefore pay more tax and claim fewer benefits.

I believe the problem is that commissioners and medical professionals, like the public, still see obesity as a lifestyle choice, and so blame patients. But there is a point of no return with obesity. There are parallels with other diseases. You may well suggest to someone who is a bit down in various ways for them to try and improve their mood, but once they become clinically depressed expert treatment is needed. We encourage our friends to stop smoking, but we don’t then begrudge them treatment for lung cancer.

Yet the reluctance to treat obesity lingers. Some argue that resources should be directed to prevention rather than treatment. Whenever possible, prevention is obviously better than cure. But this is no longer an option for people who have missed the boat of prevention and have gone on to develop severe, complex obesity with conditions such as diabetes.

Patients should be given quicker access to surgical assessment. If bariatric surgery is right for them, then the sooner the better. We already know that the UK is one of the most obese countries in Europe, and the patients we operate on are the sickest. The NHS should be performing 50,000 surgeries a year, closer to the European average.

To achieve this, health workers must be persuaded to put prejudice to one side and promote surgery where appropriate. GPs and commissioners alike must recognise both the health benefits and cost savings.

All the clinical evidence points to the fact that, as a country, we should be performing more weight-loss surgeries. It is the social stigma of obesity that is holding us back. Making fun of obese people is an endemic societal prejudice, and stigmatisation is allowed – and even encouraged – by the media. It’s time to stop judging and let the experts start treating the condition.

Richard Welbourn is a consultant bariatric surgeon at Musgrove Park Hospital, Taunton

Obese people deserve surgical treatment, too | Richard Welbourn

One in four people in the UK suffer with obesity. Severe and complex obesity is a lifelong condition associated with many major medical problems, the costs of which threaten to bankrupt the NHS. The major ailment caused by obesity – type 2 diabetes – is linked to shorter life expectancy, decreased quality of life and increased socio-economic and psychosocial problems. A new report out this week suggests the global cost of treating obesity will rise to $ 1.2tn a year from 2025.

Yet in the UK, less than 1% of those who can benefit from it receive bariatric (sometimes called weight-loss) surgery, such as gastric bypass or gastric banding. So why is a safe, cost-effective therapy for a deadly disease so under-utilised?

For severely obese people, the hormonal effects of being obese mean that medical therapies, lifestyle changes and attempts at dieting rarely succeed in maintaining long-term, clinically beneficial weight loss. It isn’t just surgeons saying this – it is described in guidance by the British Obesity and Metabolic Surgery Society which is endorsed by 21 other professional organisations, including nine medical royal colleges.

The World Health Organisation identifies obesity as a chronic disease. But on the other side we have the popular perception – shared by some healthcare professionals – that it is purely a lifestyle choice. This totally disregards the fact that, driven by powerful food industry advertising, it is those who are poor who are most affected. Our tendency towards obesity is rooted in evolutionary biology: human beings have spent two million years developing a metabolic system which conserves energy in times of scarcity. It is only in the last 70 years that we no longer eat because of hunger alone.

The annual volume of bariatric surgery in the UK – about 5,000 operations a year – is five to 10 times lower compared with other European countries with similar population sizes and disease prevalence. In France, which has a similar population size to the UK, more than 37,000 surgeries are carried out each year. Belgium, with a population of 11.3 million, undertakes 12,000 surgeries while Sweden, with a population of 9.9 million, carries out more than 7,000 a year.

As a practising bariatric surgeon, I and my colleagues believe the social stigma of obesity is holding back the deployment of cost-effective treatments for vulnerable people. Health commissioners are aware of the figures, but remain slow to increase provision. Cost can’t be the issue. Getting a patient off insulin or other expensive anti-diabetes medications is cost-saving within two to three years of surgery: a win-win for the GP, the NHS and the taxpayer. Patients are also more likely to go back to work, and therefore pay more tax and claim fewer benefits.

I believe the problem is that commissioners and medical professionals, like the public, still see obesity as a lifestyle choice, and so blame patients. But there is a point of no return with obesity. There are parallels with other diseases. You may well suggest to someone who is a bit down in various ways for them to try and improve their mood, but once they become clinically depressed expert treatment is needed. We encourage our friends to stop smoking, but we don’t then begrudge them treatment for lung cancer.

Yet the reluctance to treat obesity lingers. Some argue that resources should be directed to prevention rather than treatment. Whenever possible, prevention is obviously better than cure. But this is no longer an option for people who have missed the boat of prevention and have gone on to develop severe, complex obesity with conditions such as diabetes.

Patients should be given quicker access to surgical assessment. If bariatric surgery is right for them, then the sooner the better. We already know that the UK is one of the most obese countries in Europe, and the patients we operate on are the sickest. The NHS should be performing 50,000 surgeries a year, closer to the European average.

To achieve this, health workers must be persuaded to put prejudice to one side and promote surgery where appropriate. GPs and commissioners alike must recognise both the health benefits and cost savings.

All the clinical evidence points to the fact that, as a country, we should be performing more weight-loss surgeries. It is the social stigma of obesity that is holding us back. Making fun of obese people is an endemic societal prejudice, and stigmatisation is allowed – and even encouraged – by the media. It’s time to stop judging and let the experts start treating the condition.

Richard Welbourn is a consultant bariatric surgeon at Musgrove Park Hospital, Taunton

Obese people deserve surgical treatment, too | Richard Welbourn

One in four people in the UK suffer with obesity. Severe and complex obesity is a lifelong condition associated with many major medical problems, the costs of which threaten to bankrupt the NHS. The major ailment caused by obesity – type 2 diabetes – is linked to shorter life expectancy, decreased quality of life and increased socio-economic and psychosocial problems. A new report out this week suggests the global cost of treating obesity will rise to $ 1.2tn a year from 2025.

Yet in the UK, less than 1% of those who can benefit from it receive bariatric (sometimes called weight-loss) surgery, such as gastric bypass or gastric banding. So why is a safe, cost-effective therapy for a deadly disease so under-utilised?

For severely obese people, the hormonal effects of being obese mean that medical therapies, lifestyle changes and attempts at dieting rarely succeed in maintaining long-term, clinically beneficial weight loss. It isn’t just surgeons saying this – it is described in guidance by the British Obesity and Metabolic Surgery Society which is endorsed by 21 other professional organisations, including nine medical royal colleges.

The World Health Organisation identifies obesity as a chronic disease. But on the other side we have the popular perception – shared by some healthcare professionals – that it is purely a lifestyle choice. This totally disregards the fact that, driven by powerful food industry advertising, it is those who are poor who are most affected. Our tendency towards obesity is rooted in evolutionary biology: human beings have spent two million years developing a metabolic system which conserves energy in times of scarcity. It is only in the last 70 years that we no longer eat because of hunger alone.

The annual volume of bariatric surgery in the UK – about 5,000 operations a year – is five to 10 times lower compared with other European countries with similar population sizes and disease prevalence. In France, which has a similar population size to the UK, more than 37,000 surgeries are carried out each year. Belgium, with a population of 11.3 million, undertakes 12,000 surgeries while Sweden, with a population of 9.9 million, carries out more than 7,000 a year.

As a practising bariatric surgeon, I and my colleagues believe the social stigma of obesity is holding back the deployment of cost-effective treatments for vulnerable people. Health commissioners are aware of the figures, but remain slow to increase provision. Cost can’t be the issue. Getting a patient off insulin or other expensive anti-diabetes medications is cost-saving within two to three years of surgery: a win-win for the GP, the NHS and the taxpayer. Patients are also more likely to go back to work, and therefore pay more tax and claim fewer benefits.

I believe the problem is that commissioners and medical professionals, like the public, still see obesity as a lifestyle choice, and so blame patients. But there is a point of no return with obesity. There are parallels with other diseases. You may well suggest to someone who is a bit down in various ways for them to try and improve their mood, but once they become clinically depressed expert treatment is needed. We encourage our friends to stop smoking, but we don’t then begrudge them treatment for lung cancer.

Yet the reluctance to treat obesity lingers. Some argue that resources should be directed to prevention rather than treatment. Whenever possible, prevention is obviously better than cure. But this is no longer an option for people who have missed the boat of prevention and have gone on to develop severe, complex obesity with conditions such as diabetes.

Patients should be given quicker access to surgical assessment. If bariatric surgery is right for them, then the sooner the better. We already know that the UK is one of the most obese countries in Europe, and the patients we operate on are the sickest. The NHS should be performing 50,000 surgeries a year, closer to the European average.

To achieve this, health workers must be persuaded to put prejudice to one side and promote surgery where appropriate. GPs and commissioners alike must recognise both the health benefits and cost savings.

All the clinical evidence points to the fact that, as a country, we should be performing more weight-loss surgeries. It is the social stigma of obesity that is holding us back. Making fun of obese people is an endemic societal prejudice, and stigmatisation is allowed – and even encouraged – by the media. It’s time to stop judging and let the experts start treating the condition.

Richard Welbourn is a consultant bariatric surgeon at Musgrove Park Hospital, Taunton

Obese people deserve surgical treatment, too | Richard Welbourn

One in four people in the UK suffer with obesity. Severe and complex obesity is a lifelong condition associated with many major medical problems, the costs of which threaten to bankrupt the NHS. The major ailment caused by obesity – type 2 diabetes – is linked to shorter life expectancy, decreased quality of life and increased socio-economic and psychosocial problems. A new report out this week suggests the global cost of treating obesity will rise to $ 1.2tn a year from 2025.

Yet in the UK, less than 1% of those who can benefit from it receive bariatric (sometimes called weight-loss) surgery, such as gastric bypass or gastric banding. So why is a safe, cost-effective therapy for a deadly disease so under-utilised?

For severely obese people, the hormonal effects of being obese mean that medical therapies, lifestyle changes and attempts at dieting rarely succeed in maintaining long-term, clinically beneficial weight loss. It isn’t just surgeons saying this – it is described in guidance by the British Obesity and Metabolic Surgery Society which is endorsed by 21 other professional organisations, including nine medical royal colleges.

The World Health Organisation identifies obesity as a chronic disease. But on the other side we have the popular perception – shared by some healthcare professionals – that it is purely a lifestyle choice. This totally disregards the fact that, driven by powerful food industry advertising, it is those who are poor who are most affected. Our tendency towards obesity is rooted in evolutionary biology: human beings have spent two million years developing a metabolic system which conserves energy in times of scarcity. It is only in the last 70 years that we no longer eat because of hunger alone.

The annual volume of bariatric surgery in the UK – about 5,000 operations a year – is five to 10 times lower compared with other European countries with similar population sizes and disease prevalence. In France, which has a similar population size to the UK, more than 37,000 surgeries are carried out each year. Belgium, with a population of 11.3 million, undertakes 12,000 surgeries while Sweden, with a population of 9.9 million, carries out more than 7,000 a year.

As a practising bariatric surgeon, I and my colleagues believe the social stigma of obesity is holding back the deployment of cost-effective treatments for vulnerable people. Health commissioners are aware of the figures, but remain slow to increase provision. Cost can’t be the issue. Getting a patient off insulin or other expensive anti-diabetes medications is cost-saving within two to three years of surgery: a win-win for the GP, the NHS and the taxpayer. Patients are also more likely to go back to work, and therefore pay more tax and claim fewer benefits.

I believe the problem is that commissioners and medical professionals, like the public, still see obesity as a lifestyle choice, and so blame patients. But there is a point of no return with obesity. There are parallels with other diseases. You may well suggest to someone who is a bit down in various ways for them to try and improve their mood, but once they become clinically depressed expert treatment is needed. We encourage our friends to stop smoking, but we don’t then begrudge them treatment for lung cancer.

Yet the reluctance to treat obesity lingers. Some argue that resources should be directed to prevention rather than treatment. Whenever possible, prevention is obviously better than cure. But this is no longer an option for people who have missed the boat of prevention and have gone on to develop severe, complex obesity with conditions such as diabetes.

Patients should be given quicker access to surgical assessment. If bariatric surgery is right for them, then the sooner the better. We already know that the UK is one of the most obese countries in Europe, and the patients we operate on are the sickest. The NHS should be performing 50,000 surgeries a year, closer to the European average.

To achieve this, health workers must be persuaded to put prejudice to one side and promote surgery where appropriate. GPs and commissioners alike must recognise both the health benefits and cost savings.

All the clinical evidence points to the fact that, as a country, we should be performing more weight-loss surgeries. It is the social stigma of obesity that is holding us back. Making fun of obese people is an endemic societal prejudice, and stigmatisation is allowed – and even encouraged – by the media. It’s time to stop judging and let the experts start treating the condition.

Richard Welbourn is a consultant bariatric surgeon at Musgrove Park Hospital, Taunton

UK scientists create world’s smallest surgical robot to start a hospital revolution

British scientists have developed the world’s smallest surgical robot which could transform everyday operations for tens of thousands of patients.

From a converted pig shed in the Cambridgeshire countryside, a team of 100 scientists and engineers have used low-cost technology originally developed for mobile phones and space industries to create the first robotic arm specifically designed to carry out keyhole surgery.

The robot, called Versius, mimics the human arm and can be used to carry out a wide range of laparoscopic procedures – including hernia repairs, colorectal operations, and prostate and ear, nose and throat surgery – in which a series of small incisions are made to circumvent the need for traditional open surgery. This reduces complications and pain after surgery and speeds up recovery times for patients.

The robot is controlled by a surgeon at a console guided by a 3D screen in the operating theatre.

Although surgical robots already exist, the new creation is much easier to use, takes up about a third of the space of current machines and will be no more expensive than non-robotic keyhole surgery, according to its maker Cambridge Medical Robotics.

“Having robots in the operating theatre is not a new idea,” said the company’s chief executive, Martin Frost. “The problem at the moment is that they are phenomenally expensive – not only do they cost £2m each to buy but every procedure costs an extra £3,000 using the robot – and they are very large. Many hospitals have to use the operating theatre around the robot. Their size can also make them difficult for the surgical team to use.

“They are also poorly utilised; they are only really used for pelvic surgery, and can’t be easily adapted to other types of surgery. In some hospitals they are only being used once every other day.”

For robots to revolutionise surgery, he said, they need to be versatile, easy to use and small so that surgical staff can move them around the operating room or between operating theatres, or pack them away when they are not being used. “Our robot does all of this and is the first robotic arm to be designed specifically for laparoscopic surgery,” Frost said.

One of the key benefits of the robot is that it works like a human arm and contains technology that detects resistance to make sure the right amount of force is used when the instruments are inside the patient.

“When science wants to solve a problem, it often turns to nature,” said Luke Hares, chief technology officer at CMR. “We took our inspiration from the human arm, the greatest surgical tool in history.”

The creators looked at the joints within the human arm, he said, in particular the wrist, mapping how they performed a role to allow the hand to move so precisely and flexibly. They then replicated these movements in Versius.

“Whereas traditional industrial robotic arms are large and the wrists have three joints, our robot is the same size as a human arm and has four wrist joints, giving the surgeon an unprecedented level of freedom to operate on the patient from whatever angle they want, versatility and reach,” Hares said.

To create this sophisticated and state-of-the-art device Versius’s creators used electronics from mobile phones to help the robot “think” and process information, and gear box technology originally designed for the space industry to help it move. “The other great benefit is that the robot doesn’t tire like a surgeon can,” said Hares.

The robot will be launched next spring and, once surgeons are trained, it should be available for procedures on patients by the end of next year.

CMR said it was already working with a number of NHS and private hospitals to introduce the robots. The current global market for surgical robots is worth approximately $ 4bn a year but this is expected to grow to $ 20bn by 2024.

UK scientists create world’s smallest surgical robot to start a hospital revolution

British scientists have developed the world’s smallest surgical robot which could transform everyday operations for tens of thousands of patients.

From a converted pig shed in the Cambridgeshire countryside, a team of 100 scientists and engineers have used low-cost technology originally developed for mobile phones and space industries to create the first robotic arm specifically designed to carry out keyhole surgery.

The robot, called Versius, mimics the human arm and can be used to carry out a wide range of laparoscopic procedures – including hernia repairs, colorectal operations, and prostate and ear, nose and throat surgery – in which a series of small incisions are made to circumvent the need for traditional open surgery. This reduces complications and pain after surgery and speeds up recovery times for patients.

The robot is controlled by a surgeon at a console guided by a 3D screen in the operating theatre.

Although surgical robots already exist, the new creation is much easier to use, takes up about a third of the space of current machines and will be no more expensive than non-robotic keyhole surgery, according to its maker Cambridge Medical Robotics.

“Having robots in the operating theatre is not a new idea,” said the company’s chief executive, Martin Frost. “The problem at the moment is that they are phenomenally expensive – not only do they cost £2m each to buy but every procedure costs an extra £3,000 using the robot – and they are very large. Many hospitals have to use the operating theatre around the robot. Their size can also make them difficult for the surgical team to use.

“They are also poorly utilised; they are only really used for pelvic surgery, and can’t be easily adapted to other types of surgery. In some hospitals they are only being used once every other day.”

For robots to revolutionise surgery, he said, they need to be versatile, easy to use and small so that surgical staff can move them around the operating room or between operating theatres, or pack them away when they are not being used. “Our robot does all of this and is the first robotic arm to be designed specifically for laparoscopic surgery,” Frost said.

One of the key benefits of the robot is that it works like a human arm and contains technology that detects resistance to make sure the right amount of force is used when the instruments are inside the patient.

“When science wants to solve a problem, it often turns to nature,” said Luke Hares, chief technology officer at CMR. “We took our inspiration from the human arm, the greatest surgical tool in history.”

The creators looked at the joints within the human arm, he said, in particular the wrist, mapping how they performed a role to allow the hand to move so precisely and flexibly. They then replicated these movements in Versius.

“Whereas traditional industrial robotic arms are large and the wrists have three joints, our robot is the same size as a human arm and has four wrist joints, giving the surgeon an unprecedented level of freedom to operate on the patient from whatever angle they want, versatility and reach,” Hares said.

To create this sophisticated and state-of-the-art device Versius’s creators used electronics from mobile phones to help the robot “think” and process information, and gear box technology originally designed for the space industry to help it move. “The other great benefit is that the robot doesn’t tire like a surgeon can,” said Hares.

The robot will be launched next spring and, once surgeons are trained, it should be available for procedures on patients by the end of next year.

CMR said it was already working with a number of NHS and private hospitals to introduce the robots. The current global market for surgical robots is worth approximately $ 4bn a year but this is expected to grow to $ 20bn by 2024.

UK scientists create world’s smallest surgical robot to start a hospital revolution

British scientists have developed the world’s smallest surgical robot which could transform everyday operations for tens of thousands of patients.

From a converted pig shed in the Cambridgeshire countryside, a team of 100 scientists and engineers have used low-cost technology originally developed for mobile phones and space industries to create the first robotic arm specifically designed to carry out keyhole surgery.

The robot, called Versius, mimics the human arm and can be used to carry out a wide range of laparoscopic procedures – including hernia repairs, colorectal operations, and prostate and ear, nose and throat surgery – in which a series of small incisions are made to circumvent the need for traditional open surgery. This reduces complications and pain after surgery and speeds up recovery times for patients.

The robot is controlled by a surgeon at a console guided by a 3D screen in the operating theatre.

Although surgical robots already exist, the new creation is much easier to use, takes up about a third of the space of current machines and will be no more expensive than non-robotic keyhole surgery, according to its maker Cambridge Medical Robotics.

“Having robots in the operating theatre is not a new idea,” said the company’s chief executive, Martin Frost. “The problem at the moment is that they are phenomenally expensive – not only do they cost £2m each to buy but every procedure costs an extra £3,000 using the robot – and they are very large. Many hospitals have to use the operating theatre around the robot. Their size can also make them difficult for the surgical team to use.

“They are also poorly utilised; they are only really used for pelvic surgery, and can’t be easily adapted to other types of surgery. In some hospitals they are only being used once every other day.”

For robots to revolutionise surgery, he said, they need to be versatile, easy to use and small so that surgical staff can move them around the operating room or between operating theatres, or pack them away when they are not being used. “Our robot does all of this and is the first robotic arm to be designed specifically for laparoscopic surgery,” Frost said.

One of the key benefits of the robot is that it works like a human arm and contains technology that detects resistance to make sure the right amount of force is used when the instruments are inside the patient.

“When science wants to solve a problem, it often turns to nature,” said Luke Hares, chief technology officer at CMR. “We took our inspiration from the human arm, the greatest surgical tool in history.”

The creators looked at the joints within the human arm, he said, in particular the wrist, mapping how they performed a role to allow the hand to move so precisely and flexibly. They then replicated these movements in Versius.

“Whereas traditional industrial robotic arms are large and the wrists have three joints, our robot is the same size as a human arm and has four wrist joints, giving the surgeon an unprecedented level of freedom to operate on the patient from whatever angle they want, versatility and reach,” Hares said.

To create this sophisticated and state-of-the-art device Versius’s creators used electronics from mobile phones to help the robot “think” and process information, and gear box technology originally designed for the space industry to help it move. “The other great benefit is that the robot doesn’t tire like a surgeon can,” said Hares.

The robot will be launched next spring and, once surgeons are trained, it should be available for procedures on patients by the end of next year.

CMR said it was already working with a number of NHS and private hospitals to introduce the robots. The current global market for surgical robots is worth approximately $ 4bn a year but this is expected to grow to $ 20bn by 2024.

UK scientists create world’s smallest surgical robot to start a hospital revolution

British scientists have developed the world’s smallest surgical robot which could transform everyday operations for tens of thousands of patients.

From a converted pig shed in the Cambridgeshire countryside, a team of 100 scientists and engineers have used low-cost technology originally developed for mobile phones and space industries to create the first robotic arm specifically designed to carry out keyhole surgery.

The robot, called Versius, mimics the human arm and can be used to carry out a wide range of laparoscopic procedures – including hernia repairs, colorectal operations, and prostate and ear, nose and throat surgery – in which a series of small incisions are made to circumvent the need for traditional open surgery. This reduces complications and pain after surgery and speeds up recovery times for patients.

The robot is controlled by a surgeon at a console guided by a 3D screen in the operating theatre.

Although surgical robots already exist, the new creation is much easier to use, takes up about a third of the space of current machines and will be no more expensive than non-robotic keyhole surgery, according to its maker Cambridge Medical Robotics.

“Having robots in the operating theatre is not a new idea,” said the company’s chief executive, Martin Frost. “The problem at the moment is that they are phenomenally expensive – not only do they cost £2m each to buy but every procedure costs an extra £3,000 using the robot – and they are very large. Many hospitals have to use the operating theatre around the robot. Their size can also make them difficult for the surgical team to use.

“They are also poorly utilised; they are only really used for pelvic surgery, and can’t be easily adapted to other types of surgery. In some hospitals they are only being used once every other day.”

For robots to revolutionise surgery, he said, they need to be versatile, easy to use and small so that surgical staff can move them around the operating room or between operating theatres, or pack them away when they are not being used. “Our robot does all of this and is the first robotic arm to be designed specifically for laparoscopic surgery,” Frost said.

One of the key benefits of the robot is that it works like a human arm and contains technology that detects resistance to make sure the right amount of force is used when the instruments are inside the patient.

“When science wants to solve a problem, it often turns to nature,” said Luke Hares, chief technology officer at CMR. “We took our inspiration from the human arm, the greatest surgical tool in history.”

The creators looked at the joints within the human arm, he said, in particular the wrist, mapping how they performed a role to allow the hand to move so precisely and flexibly. They then replicated these movements in Versius.

“Whereas traditional industrial robotic arms are large and the wrists have three joints, our robot is the same size as a human arm and has four wrist joints, giving the surgeon an unprecedented level of freedom to operate on the patient from whatever angle they want, versatility and reach,” Hares said.

To create this sophisticated and state-of-the-art device Versius’s creators used electronics from mobile phones to help the robot “think” and process information, and gear box technology originally designed for the space industry to help it move. “The other great benefit is that the robot doesn’t tire like a surgeon can,” said Hares.

The robot will be launched next spring and, once surgeons are trained, it should be available for procedures on patients by the end of next year.

CMR said it was already working with a number of NHS and private hospitals to introduce the robots. The current global market for surgical robots is worth approximately $ 4bn a year but this is expected to grow to $ 20bn by 2024.

UK scientists create world’s smallest surgical robot to start a hospital revolution

British scientists have developed the world’s smallest surgical robot which could transform everyday operations for tens of thousands of patients.

From a converted pig shed in the Cambridgeshire countryside, a team of 100 scientists and engineers have used low-cost technology originally developed for mobile phones and space industries to create the first robotic arm specifically designed to carry out keyhole surgery.

The robot, called Versius, mimics the human arm and can be used to carry out a wide range of laparoscopic procedures – including hernia repairs, colorectal operations, and prostate and ear, nose and throat surgery – in which a series of small incisions are made to circumvent the need for traditional open surgery. This reduces complications and pain after surgery and speeds up recovery times for patients.

The robot is controlled by a surgeon at a console guided by a 3D screen in the operating theatre.

Although surgical robots already exist, the new creation is much easier to use, takes up about a third of the space of current machines and will be no more expensive than non-robotic keyhole surgery, according to its maker Cambridge Medical Robotics.

“Having robots in the operating theatre is not a new idea,” said the company’s chief executive, Martin Frost. “The problem at the moment is that they are phenomenally expensive – not only do they cost £2m each to buy but every procedure costs an extra £3,000 using the robot – and they are very large. Many hospitals have to use the operating theatre around the robot. Their size can also make them difficult for the surgical team to use.

“They are also poorly utilised; they are only really used for pelvic surgery, and can’t be easily adapted to other types of surgery. In some hospitals they are only being used once every other day.”

For robots to revolutionise surgery, he said, they need to be versatile, easy to use and small so that surgical staff can move them around the operating room or between operating theatres, or pack them away when they are not being used. “Our robot does all of this and is the first robotic arm to be designed specifically for laparoscopic surgery,” Frost said.

One of the key benefits of the robot is that it works like a human arm and contains technology that detects resistance to make sure the right amount of force is used when the instruments are inside the patient.

“When science wants to solve a problem, it often turns to nature,” said Luke Hares, chief technology officer at CMR. “We took our inspiration from the human arm, the greatest surgical tool in history.”

The creators looked at the joints within the human arm, he said, in particular the wrist, mapping how they performed a role to allow the hand to move so precisely and flexibly. They then replicated these movements in Versius.

“Whereas traditional industrial robotic arms are large and the wrists have three joints, our robot is the same size as a human arm and has four wrist joints, giving the surgeon an unprecedented level of freedom to operate on the patient from whatever angle they want, versatility and reach,” Hares said.

To create this sophisticated and state-of-the-art device Versius’s creators used electronics from mobile phones to help the robot “think” and process information, and gear box technology originally designed for the space industry to help it move. “The other great benefit is that the robot doesn’t tire like a surgeon can,” said Hares.

The robot will be launched next spring and, once surgeons are trained, it should be available for procedures on patients by the end of next year.

CMR said it was already working with a number of NHS and private hospitals to introduce the robots. The current global market for surgical robots is worth approximately $ 4bn a year but this is expected to grow to $ 20bn by 2024.